Multi-Gene panel-based genetic testing has emerged as the standard of care for cancer genetic testing. This has led to the identification of TP53 mutations among individuals without classic personal or family histories of Li-Fraumeni syndrome. These mutations may be due to mosaicism, clonal hematopoiesis, or due to form fruste Li-Fraumeni syndrome. We will discuss how these findings are shaping clinical cancer genetics care and how they are leading to a re-evaluation of the epidemiology and penetrance of germline TP53 mutations.
The Clinical Impact of TP53 Inclusion in Multi-Gene Panels with Huma Q. Rana, MD
Dr. Huma Q. Rana is a physician at Dana Farber Cancer Institute, board certified in Internal Medicine and Clinical Genetics. She received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her Internal Medicine and Genetics training at Mount Sinai School of Medicine in New York, and joined Dana-Farber in 2012.
At Dana-Farber, she is the Clinical Director of the Center for Cancer Genetics and Prevention. She provides longitudinal medical management of patients with hereditary cancer predispositions, and also leads multiple research projects studying various hereditary cancer syndromes.
Brooke Overstreet, MS, CGC received her bachelor’s and master’s degrees in Molecular and Cellular Biology from the University of Arizona. She went on to receive her master’s degree in Genetic Counseling from the University of Cincinnati. Brooke was a clinical genetic counselor at the Mayo Clinic in Arizona for three years where she counseled adult patients for oncology, neurology, cardiology and healthy exome. She joined Ambry in 2017 as an oncology genetic specialist.
- Fri, February 8, 2019
- 12:00pm PST
- Duration: 1 hour
-
C.E.U.
1 Category 1 Contact Hour
- P.A.C.E. 1 unit